Spots Global Cancer Trial Database for Biomarkers in Blood and Tumor Tissue Samples From Patients With Wilms Tumor

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Biomarkers in Blood and Tumor Tissue Samples From Patients With Wilms Tumor

Official Title: Pilot Case-Control Study of WT1 Mutations in Wilms Tumor Patients Who Develop ESRD

Study ID: NCT01314391

Conditions

Kidney Cancer

Renal Failure

Interventions

mutation analysis

polymerase chain reaction

laboratory biomarker analysis

Study Description

Brief Summary: RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research study is studying biomarkers in blood and tumor tissue samples from patients with Wilms tumor.

Detailed Description: OBJECTIVES: * To determine whether Wilms Tumor (WT) patients without WT1-associated congenital anomalies or syndromes, but with end-stage renal disease (ESRD) unrelated to progressive bilateral tumors, carry germline WT1 mutations. * To determine whether non-syndromic WT1 germline mutation carriers have a substantially higher incidence of ESRD than do WT patients who do not harbor WT1 mutations. OUTLINE: Archived blood and tumor tissue specimens (or DNA isolated from these samples) are analyzed for WT1 mutations by gene sequencing and PCR.